What is your preferred 1L treatment for newly diagnosed Del(17p)/TP53 mutation, high-risk CLL?

For patients with TN-CLL with TP53 aberration, the treatment options are usually based on patient factors. If a patient is a candidate for combination therapy, I prefer to treat them with uMRD-guided BTKi+BCL2i ± CD20 mAb. I only add a CD20 mAb to patients with no history of frequent infections and ...

I don't have a preference for one particular treatment for del17p/TP53-mutated CLL. The conversation around 1L treatment is similar for all patients with CLL, which involves discussing fixed-duration vs. continuous treatment regimens. For patients with CLL with del17p or TP53 mutations, this discuss...